Rabnawaz Khan*
This study presents the dynamic boost of the COVID-19 vaccines. The intensive approach is indicating how the effective COVID-19 vaccine promotes and distributes into various official channels. The Cost-Effectiveness Analysis (CEA) approach is used with Quality-Adjusted Life Years (QALYs). The key findings are revealing the length of life improves the quality of life of the middle family. The QALYs show that Utility Value (UV) by health and the value of statistics in countries in the term of coexistent causation of vaccines. The Pfizer (BNT162b2) and Moderna (mRNA- 1273) have instantly created favourable and significant effects probably on many patients, comparatively SARSCoV- 2, AstraZeneca (AZD1222), Russia’s Sputnik (AstraZeneca), and Sinopharm Sinovac Biotech. The opportunity cost provides a valuable benefit in the future.